Fenugreek

What it is

Fenugreek is an annual legume in the family Fabaceae, grown for its aromatic golden-yellow seeds and its leaves. Both are long-standing foods in Indian, Iranian, Turkish, Georgian, Egyptian and Ethiopian cooking, and the seed is also used medicinally. The seed is rich in soluble fibre and contains alkaloids, flavonoids, saponins and the amino acid derivative 4-hydroxyisoleucine, plus sotolon, the compound responsible for its maple-syrup smell.

What the research says

Fenugreek seed is promoted mainly for blood sugar, for cholesterol and as a galactagogue to increase breast milk. For glucose the meta-analytic picture is positive but unstable: one meta-analysis of 26 randomised trials reported significant falls in fasting glucose, post-meal glucose, HbA1c and insulin, while a 2023 meta-analysis of 14 trials found the fasting glucose change non-significant and reported heterogeneity of I-squared 99%. The 26-trial abstract also prints two of its own figures inconsistently, so its numbers for post-meal glucose and insulin resistance should not be relied on. Both sets of authors say the trials are largely poor quality. Reported harms are mostly mild and self-limiting, but they include hypoglycaemia, a fall in serum potassium, allergic reactions with cross-reactivity to chickpeas and peanuts, reported liver toxicity, a bleeding interaction with warfarin, and a maple-syrup odour in urine, sweat and possibly breast milk.

Evidence grade: Limited evidence.

What goes wrong

A scoping review of 60 articles found hypoglycaemia, possible hypokalaemia, allergic reactions, a maple-syrup odour in urine, sweat or skin, and drug interactions among reported human adverse effects of fenugreek. (Source 1)

• Systematic review, Low certainty.
• Size: 60 articles, including 50 clinical trials and 10 case reports or case series.
• Who: humans consuming fenugreek, including trial participants, mothers and infants.
• How long: literature from January 1990 to September 2024.
• Result: 14 of 50 clinical trials reported adverse effects, 23 reported none, 13 gave no information; 10 case reports or series described allergic or hypersensitivity reactions.
• Funding: not stated.

Other reported effects included hypoglycemia, potential hypokalemia, allergic reactions, a maple syrup odor in the urine, sweat, or skin of infants and mothers, and interactions with certain medications.

The NIH LactMed monograph records liver toxicity reports, a 14% fall in serum potassium, asthma exacerbation, allergic reactions including one case of toxic epidermal necrolysis, and cross-reactivity with chickpeas and peanuts. (Source 2)

• Official position, Certainty not rated.
• Size: case reports and one US survey of 85 mothers who used fenugreek as a galactagogue.
• Who: adults, mostly breastfeeding women, taking fenugreek medicinally.
• How long: not applicable - curated database, revised 15 July 2026.
• Result: 45% of 85 surveyed mothers reported an adverse reaction; 14% decrease in serum potassium reported.
• Funding: US government database.

Allergic reactions, exacerbation of asthma, and a 14% decrease in serum potassium have been reported.

LactMed records that fenugreek can interact with warfarin to cause bleeding and advises caution at high doses in women with diabetes or on warfarin. (Source 2)

• Official position, Certainty not rated.
• Size: not quantified in the monograph.
• Who: adults taking fenugreek alongside warfarin or glucose-lowering treatment.
• How long: not applicable - curated database, revised 15 July 2026.
• Result: bleeding risk with warfarin; blood-sugar lowering at about 25 g/day or more, which is the basis of the diabetes caution.
• Funding: US government database.

It can also interact with warfarin to cause bleeding. Caution should be used in giving high dosages to women with diabetes mellitus or those taking warfarin.

In a United States survey of nursing mothers reported in LactMed, 45% of the 85 who had used fenugreek as a galactagogue reported an adverse reaction. (Source 2)

• Survey study, Very low certainty.
• Size: 85 mothers who had used fenugreek.
• Who: nursing mothers in the United States.
• How long: not stated.
• Result: 45% reported having experienced an adverse reaction from the supplement.
• Funding: not stated.

In a survey of nursing mothers in the United States, 85 had used fenugreek as a galactogogue and 45% reported having experienced an adverse reaction from the supplement.

Fenugreek's sotolon content transfers a maple-syrup odour to urine, sweat, faeces and possibly breast milk, which can be mistaken for the inherited disorder maple syrup urine disease. (Source 2)

• Official position, Certainty not rated.
• Size: not quantified in the monograph.
• Who: adults and breastfed infants exposed to fenugreek.
• How long: not applicable - curated database, revised 15 July 2026.
• Result: odour in urine, sweat, faeces and possibly breastmilk attributed to sotolon.
• Funding: US government database.

Perhaps its most unusual side effect is the imparting an odor of maple syrup to the urine, sweat, feces, and possibly breastmilk by the sotolon in fenugreek.

What the evidence supports

A meta-analysis of 26 randomised controlled trials found significant reductions in fasting glucose, two-hour post-prandial glucose, HbA1c and insulin with fenugreek seed. (Source 3)

• Meta-analysis, Low certainty.
• Size: 26 randomised controlled trials.
• Who: participants in trials of fenugreek seed reporting glycaemic parameters.
• How long: not stated in the abstract.
• Result: FBG WMD -16.75 mg/dl (95% CI -23.36, -10.15; p<0.001); 2hPP WMD -22.28 mg/dl (95% CI -34.42 to -10.15; p<0.001; I-squared 95.1%); HbA1c WMD -0.63 (95% CI -0.76 to -0.51; p<0.001); insulin SMD -0.42 (95% CI -0.79 to -0.05; p = 0.026)
• Funding: not stated.

Limit of this finding: Read the numbers in this abstract with care: the journal has printed two of them inconsistently. The confidence interval it gives for two-hour post-meal glucose ends on the same number (-10.15) as the one it gives for fasting glucose, which looks like a copy-and-paste slip, and the value it gives for insulin resistance (HOMA-IR) is printed as the same number as the post-meal glucose estimate and in mg/dl, a unit HOMA-IR is not measured in. The fasting glucose result quoted here is the figure to go by; the post-meal interval and the insulin-resistance figure should not be relied on.

The results indicated significant improving effects of fenugreek on FBG (WMD: − 16.75 mg/dl; 95 % CI: − 23.36, − 10.15; p<0.001)

What the evidence does not support

In the same meta-analysis the effect on insulin resistance measured by HOMA-IR was not statistically significant. (Source 3)

• Meta-analysis, Low certainty.
• Size: subset of the 26 randomised controlled trials reporting HOMA-IR.
• Who: participants in fenugreek trials reporting insulin resistance.
• How long: not stated in the abstract.
• Result: HOMA-IR 95% CI -0.84 to 0.02; p = 0.061.
• Funding: not stated.

Limit of this finding: The figure in this quote is copied exactly as the journal printed it, and the journal's own abstract is wrong there: "-22.28 mg/dl" is the same number the abstract gives for two-hour post-meal glucose, and mg/dl is not a unit insulin resistance (HOMA-IR) is measured in, while the interval printed beside it (-0.84 to 0.02) is on a scale HOMA-IR plausibly uses. What can be taken from this result is only that the effect was not statistically significant (p = 0.061). The -22.28 figure itself should not be relied on and is not used in the claim above.

However, the HOMA-IR effect was insignificant (WMD: -22.28 mg/dl; 95 % CI: - 0.84 to 0.02; p = 0.061).

A 2023 meta-analysis of 14 trials found no significant change in fasting or postprandial blood glucose with fenugreek, with only HbA1c reaching significance. (Source 4)

• Meta-analysis, Very low certainty.
• Size: 14 trials, 894 participants.
• Who: participants treated with fenugreek versus control, assessed for fasting glucose, postprandial glucose and HbA1c.
• How long: not stated in the abstract.
• Result: fasting glucose MD 3.70 (95% CI -27.02, 19.62; p = 0.76); postprandial glucose MD -10.61 (95% CI -68.48, 47.26; p = 0.72); HbA1c MD -0.88 (95% CI -1.49, -0.27; p = 0.00)
• Funding: not stated.

Limit of this finding: This paper calls its fasting blood glucose result "a reduction", but the number it reports (MD: 3.70) is positive, which points the other way, and its confidence interval (-27.02 to 19.62) straddles zero with p = 0.76, so no difference was demonstrated. The same is true of the post-meal glucose result (p = 0.72). Only the HbA1c result (MD: -0.88; p = 0.00) was statistically significant. This source should not be read as evidence that fenugreek lowers fasting blood glucose.

The results showed a reduction in fasting blood glucose levels (MD: 3.70, 95% CI of −27.02, 19.62; p = 0.76), postprandial blood glucose (MD: −10.61, 95% CI of −68.48, 47.26; p = 0.72), and HbA1c (MD: −0.88, 95% CI −1.49, −0.27; p = 0.00) with fenugreek consumption.

The 2023 meta-analysis reported highly significant statistical heterogeneity, that only 4 of its 14 trials were of high quality, and funnel-plot asymmetry raising the possibility of publication bias, although its Egger test found no small-study effects. (Source 4)

• Meta-analysis, Very low certainty.
• Size: 14 trials, 894 participants.
• Who: participants in fenugreek glycaemia trials.
• How long: not stated in the abstract.
• Result: heterogeneity reported in the full text as "Heterogeneity among the studies was found to be highly significant (t2 = 1761.14, I2 = 99.37%)"; "Of the 14 trials, only 4 were of high quality."; funnel plots showed dissymmetry indicating the possibility of publication bias, while the regression-based Egger test found no small study effects (p = 0.237)
• Funding: not stated.

Limit of this finding: This paper calls its fasting blood glucose result "a reduction", but the number it reports (MD: 3.70) is positive, which points the other way, and its confidence interval (-27.02 to 19.62) straddles zero with p = 0.76, so no difference was demonstrated. The same is true of the post-meal glucose result (p = 0.72). Only the HbA1c result (MD: -0.88; p = 0.00) was statistically significant. This source should not be read as evidence that fenugreek lowers fasting blood glucose.

While this review and included trials that found beneficial effects of fenugreek consumption on glycemic control, the quality and heterogeneity of studies remain a concern.

NCCIH's position, last updated November 2023, is that research on herbal supplements for diabetes including fenugreek has been limited in number, size and quality and has not proven any of them effective. (Source 5)

• Official position, Certainty not rated.
• Size: not applicable - agency summary.
• Who: people with diabetes considering herbal supplements.
• How long: not applicable.
• Result: no effectiveness established.
• Funding: US government agency.

research has been limited in the number, size, and quality of studies and hasn't proven that any of these herbal supplements are effective

Where the evidence is mixed

The same scoping review found no deaths attributed to fenugreek and judged most reported effects mild and self-limiting. (Source 1)

• Systematic review, Low certainty.
• Size: 60 articles.
• Who: humans consuming fenugreek.
• How long: literature from January 1990 to September 2024.
• Result: no fatalities identified; commonest adverse effect mild gastrointestinal discomfort.
• Funding: not stated.

Fenugreek is generally considered safe, with most reported side effects being mild and self-limiting. No fatalities have been attributed to its use.

Where the research disagrees

Whether fenugreek seed lowers fasting blood glucose

• Authors of the 26-trial meta-analysis in Avicenna Journal of Phytomedicine, meta-analysis of 26 randomised controlled trials: The results indicated significant improving effects of fenugreek on FBG (WMD: − 16.75 mg/dl; 95 % CI: − 23.36, − 10.15; p<0.001) (Source 3)
• Authors of the 14-trial meta-analysis in Medicina (2023), meta-analysis of 14 trials, 894 participants, I-squared 99%: The results showed a reduction in fasting blood glucose levels (MD: 3.70, 95% CI of −27.02, 19.62; p = 0.76), postprandial blood glucose (MD: −10.61, 95% CI of −68.48, 47.26; p = 0.72), and HbA1c (MD: −0.88, 95% CI −1.49, −0.27; p = 0.00) with fenugreek consumption. (Source 4)

How much

• Reference intake: No recommended dietary allowance or adequate intake exists for fenugreek. It is a culinary seed and herbal medicine rather than an essential nutrient, so no body has set a reference intake and there is no recognised deficiency state. (Source 6)
• Upper limit: We found no tolerable upper intake level or acceptable daily intake set for fenugreek by any body we could reach. The nearest quantified statement is the NIH LactMed monograph's note that doses of about 25 grams or more daily may lower cholesterol and blood sugar, which is the basis for its caution in people with diabetes or taking warfarin. (Source 2)
• Studied: LactMed records that doses typically used to increase milk supply are 1 to 6 grams daily, and that about 25 grams or more daily may lower cholesterol and blood sugar. (Source 2)
• Studied: The 2023 meta-analysis pooled 14 trials with 894 participants measuring fasting glucose, postprandial glucose and HbA1c after fenugreek versus control. (Source 4)

A common belief, and what the research shows

The belief: Fenugreek is just a kitchen spice, so taking it in capsules to boost milk supply or lower blood sugar carries no risk.

What the research shows: The dose used medicinally is far above culinary amounts, and the reported harms follow the dose. NIH's LactMed monograph states that "Allergic reactions, exacerbation of asthma, and a 14% decrease in serum potassium have been reported." and that "It can also interact with warfarin to cause bleeding. Caution should be used in giving high dosages to women with diabetes mellitus or those taking warfarin." In one United States survey, "85 had used fenugreek as a galactogogue and 45% reported having experienced an adverse reaction from the supplement." A scoping review of 60 articles did conclude that "Fenugreek is generally considered safe, with most reported side effects being mild and self-limiting. No fatalities have been attributed to its use.", so the point is not that fenugreek is dangerous but that it is pharmacologically active, and people allergic to chickpeas or peanuts may cross-react.

Questions and answers

What is it?

Fenugreek is a legume herb whose golden-yellow seeds and leaves are used both as food and as medicine, and it has been used in the Indian medicine system since ancient times. The seed contains alkaloids, flavonoids, saponins, soluble fibre and fatty acids. Supplements are usually seed powder or a seed extract. (Source 6)

What does it do in the body?

In pooled randomised trials fenugreek seed was associated with lower fasting glucose, lower two-hour post-meal glucose, lower HbA1c and lower insulin, though the effect on insulin resistance was not significant. It is also used to try to increase breast milk. The trials behind these numbers are mostly small and of low quality, so treat the size of the effect as uncertain. (Source 3)

Is it good or bad for you?

Mostly benign at food amounts, and mostly mild in its side effects at medicinal doses, but it is not inert. A scoping review of 60 articles found no fatalities and mostly mild, self-limiting effects, while also documenting hypoglycaemia, low potassium, allergy and drug interactions. Whether it is 'good' for blood sugar depends on which meta-analysis you read, because they disagree on fasting glucose. (Source 1)

How do you get more of it?

From the seeds and leaves in cooking, and from seed powder or extract capsules. The doses recorded in the literature are 1 to 6 grams daily when used to try to increase milk supply, and about 25 grams or more daily before cholesterol and blood sugar effects are noted. Those are the amounts studied, not advice. (Source 2)

If it is harmful, what reduces it?

There is no described method of clearing fenugreek from the body; the literature deals with avoidance instead. The specific situations flagged are concurrent warfarin, where bleeding has been reported, and high doses in people with diabetes, where the blood-sugar lowering adds to medication. Most other reported effects are mild and settle when intake stops. (Source 2)

Why might someone be low in it or missing it?

The question does not apply in the nutrient sense. Fenugreek is a herb and spice, not a substance the body requires, so nobody is deficient in it; intake is simply a matter of whether it is part of your cooking or supplement routine. There is no absorption disorder or medicine that creates a fenugreek requirement. (Source 6)

Which whole foods contain it or feed it?

The seeds and leaves themselves are the food source. They are a standard part of Iranian, Turkish, Georgian, Egyptian and Ethiopian cooking, and in India the leaves and seeds go into pickles and traditional curries. Sprouted seeds and the leaf vegetable methi are the whole-food forms. (Source 7)

What happens if you do not have it?

Nothing identifiable happens, because there is no fenugreek deficiency. The honest framing is the reverse: even when people do take it, one meta-analysis of 14 trials found no significant change in fasting or post-meal glucose, so not taking it is not known to cost anything measurable. (Source 4)

How can you test for it?

No validated laboratory test for fenugreek status or intake was found in the literature we searched. The one recognisable marker of exposure is not a test at all but a smell: sotolon from fenugreek gives urine, sweat and faeces a maple-syrup odour, which in infants has been confused with the inherited disorder maple syrup urine disease. (Source 2)

We searched: Searched for fenugreek biomarkers, sotolon or trigonelline measurement as a status test, and checked the 2024 scoping review of fenugreek adverse effects, the 2023 and 26-trial meta-analyses and the NIH LactMed monograph; none describes a validated test for fenugreek status or intake.

References

1. Iranian Journal of Medical Sciences. Exploring the Adverse Effects of Fenugreek in Humans: A Scoping Review. 2025. DOI 10.30476/ijms.2025.106073.4017. Read the source
2. National Institute of Child Health and Human Development, NCBI Bookshelf. Fenugreek - Drugs and Lactation Database (LactMed). 2026. Read the source
3. Avicenna Journal of Phytomedicine. The effects of fenugreek (Trigonella foenum-graecum) seed on glycemic parameters: An updated systematic review and meta-analysis of randomized controlled trials. year not shown on the article page; re-checked 2026-09-23 and still not displayed. PMID 41509111. Read the source
4. Medicina (MDPI). Effect of Fenugreek on Hyperglycemia: A Systematic Review and Meta-Analysis. 2023. DOI 10.3390/medicina59020248. Read the source
5. National Center for Complementary and Integrative Health (NCCIH), NIH. Diabetes and Dietary Supplements: What You Need To Know. 2023. Read the source
6. South African Journal of Botany. Fenugreek (Trigonella foenum-graecum): Nutraceutical values, phytochemical, ethnomedicinal and pharmacological overview. 2022. DOI 10.1016/j.sajb.2022.04.014. Read the source
7. South African Journal of Botany. Fenugreek (Trigonella foenum-graecum): Nutraceutical values, phytochemical, ethnomedicinal and pharmacological overview - traditional knowledge section. 2022. DOI 10.1016/j.sajb.2022.04.014. Read the source